Moreover, the target genes (MCL1, AP2B1, LAMB1, and RAB11FIP2), and their methylation states can be considered as treatment targets of patients with GC, and high-risk patients would accept additional therapeutic intervention. This evidence concerns the gene MCL1 and gastric cancer.